Vanguard Group
ELVN icon

Vanguard Group’s Enliven Therapeutics ELVN Stock Holding History

Vanguard Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$43.1M Buy
2,801,665
+248,651
+10% +$4.95M ﹤0.01% 2243
2025
Q3 		$52.3M Buy
2,553,014
+142,378
+6% +$2.87M ﹤0.01% 2131
2025
Q2 		$48.4M Buy
2,410,636
+438,397
+22% +$8.3M ﹤0.01% 2137
2025
Q1 		$38.8M Sell
1,972,239
-3,416
-0.2% -$73.5K ﹤0.01% 2201
2024
Q4 		$44.5M Buy
1,975,655
+55,283
+3% +$1.43M ﹤0.01% 2212
2024
Q3 		$49M Buy
1,920,372
+98,912
+5% +$2.29M ﹤0.01% 2186
2024
Q2 		$42.6M Buy
1,821,460
+638,194
+54% +$13.4M ﹤0.01% 2210
2024
Q1 		$20.8M Sell
1,183,266
-47,622
-4% -$731K ﹤0.01% 2578
2023
Q4 		$17M Buy
1,230,888
+79,071
+7% +$967K ﹤0.01% 2666
2023
Q3 		$15.7M Buy
1,151,817
+9,313
+0.8% +$157K ﹤0.01% 2648
2023
Q2 		$23.3M Buy
1,142,504
+990,590
+652% +$20M ﹤0.01% 2529
2023
Q1 		$3.33M Buy
151,914
+41,611
+38% +$846K ﹤0.01% 3492
2022
Q4 		$1.8M Buy
110,303
+34,264
+45% +$548K ﹤0.01% 3702
2022
Q3 		$693K Buy
76,039
+9,617
+14% +$56.8K ﹤0.01% 4113
2022
Q2 		$324K Hold
66,422
– – ﹤0.01% 4389
2022
Q1 		$500K Sell
66,422
-54,554
-45% -$360K ﹤0.01% 4399
2021
Q4 		$1.09M Sell
120,976
-250
-0.2% -$3.28K ﹤0.01% 4245
2021
Q3 		$1.98M Buy
121,226
+73,373
+153% +$1.52M ﹤0.01% 4057
2021
Q2 		$1.51M Sell
47,853
-9,674
-17% -$300K ﹤0.01% 4047
2021
Q1 		$1.94M Buy
57,527
+5,017
+10% +$255K ﹤0.01% 3868
2020
Q4 		$4.63M Buy
52,510
+4,429
+9% +$372K ﹤0.01% 3397
2020
Q3 		$3.91M Sell
48,081
-1,093
-2% -$98.6K ﹤0.01% 3276
2020
Q2 		$5.43M Buy
49,174
+39,843
+427% +$4.46M ﹤0.01% 3061
2020
Q1 		$599K Buy
+9,331
New +$595K ﹤0.01% 3635

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group's ELVN Position: Q4 2025 in Review

Vanguard Group increased its Enliven Therapeutics (ELVN) stake by 9.7% in Q4 2025, buying an estimated $4.95M and bringing the position to 2,801,665 shares worth $43.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

Vanguard Group first reported a position in ELVN in Q1 2020 and has held it in 24 quarters since. The position peaked at $52.3M in Q3 2025. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

  • Vanguard Group held 2,801,665 shares of Enliven Therapeutics worth $43.1M as of Q4 2025.
  • Vanguard Group bought 248,651 Enliven Therapeutics shares in Q4 2025, an estimated $4.95M.
  • Enliven Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2243 holding.
  • Vanguard Group first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Vanguard Group's Enliven Therapeutics position peaked at $52.3M in Q3 2025.
  • 125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.